SwissA Healthcare
                                                                                                           
Verified Supplier
Years
Since
Menu
Home Products Skin Peptide Injection

Skin Peptide Injection

China Weight Loss Skin Peptide Injection Intravenous Sterile Powder for sale

Weight Loss Skin Peptide Injection Intravenous Sterile Powder

Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable

PEP for Injection is a first-in-class, once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, as well as for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. As a dual incretin agonist, PEP uniquely activates both GLP-1 and GIP receptors, providing

China Colorless Injectable Peptides PEP For Weight Loss Preservative Free OEM for sale

Colorless Injectable Peptides PEP For Weight Loss Preservative Free OEM

Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable

PEP for Injection is a first-in-class, once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, as well as for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. As a dual incretin agonist, PEP uniquely activates both GLP-1 and GIP receptors, providing

China Subcutaneous Zeptriva Pep Skin Peptide Injection 30mg 2ml for sale

Subcutaneous Zeptriva Pep Skin Peptide Injection 30mg 2ml

Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable

Zeptriva 30mg 2ml PEP for Injection is a first-in-class, once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, as well as for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. As a dual incretin agonist, PEP uniquely activates both GLP-1 and GIP